13F Holdings
中文EN

IMNN Imunon, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 749647 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-4.9%
TTM EPS YoY60.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-448.6%
ROA-143.2%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets78.2%
Debt / equity0.00x
Current ratio1.38x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.92x
Accruals ratio-11.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue———$500,000$500,000
R&D expense$7.78M$11.64M$11.29M$11.73M$10.62M
SG&A expense$6.87M$7.49M$9.74M$13.69M$10.89M
Operating income-$14.65M-$19.13M-$21.03M-$24.92M-$21.01M
Interest expense——$197,080$5.03M$569,881
Pretax income$14.50M$18.60M-$20.80M-$37.47M-$22.15M
Income tax——-$1.28M-$1.57M-$1.38M
Net income-$14.50M-$18.62M-$19.51M-$35.90M-$20.77M
EBITDA-$14.36M-$18.89M-$20.78M-$24.72M-$20.30M
EPS (basic)-6.83-16.94-2.16-5.03-3.83
EPS (diluted)-6.83-16.94-2.16-5.03-3.83
Weighted avg. shares (diluted)2.12M1.10M9.05M7.14M5.43M
Balance sheet
Cash & equivalents$8.78M$5.87M$5.84M$11.49M$19.59M
Short-term investments——$9.86M$21.23M$29.81M
Current assets$10.72M$8.01M$18.24M$36.78M$51.95M
PP&E, net$529,936$541,272$751,906$548,301$477,011
Total assets$12.29M$9.72M$21.92M$43.98M$74.05M
Current liabilities$4.62M$4.79M$7.39M$10.04M$6.77M
Long-term debt———$5.96M—
Total debt———$5.96M—
Total liabilities$5.23M$5.47M$8.53M$14.65M$18.25M
Shareholders' equity$7.06M$4.24M$13.39M$29.33M$55.80M
Net debt———-$5.53M—
Shares outstanding3.42M966,7129.40M7.44M5.77M
Cash flow statement
Operating cash flow-$13.90M-$18.85M-$19.02M-$23.10M-$16.22M
Capital expenditure$280,572$29,541$451,759$267,800$311,613
Free cash flow-$14.18M-$18.88M-$19.47M-$23.36M-$16.54M
Investing cash flow-$280,572$9.83M$11.01M$8.28M-$30.12M
Financing cash flow$17.09M$9.06M-$3.64M$6.72M$54.77M
Depreciation & amortization$291,908$240,175$248,000$197,000$702,918
Stock-based compensation$127,374$477,256$759,013$2.67M$3.76M

Free plan shows the latest 5 periods; Pro shows all 16 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.